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1 Our aim was to determine whether lipoamino acid conjugation of peptides that are high-affinity
activators of ryanodine receptor (RyR) channels would (a) render the peptides membrane permeable,
(b) alter their structure or (a) reduce their activity. The peptides correspond to the A region of the
II–III loop of the skeletal dihydropyridine receptor.
2 The lipoamino acid conjugation increased the apparent permeability of the peptide across the
Caco-2 cell monolayer by up to B20-fold.
3 Nuclear magnetic resonance showed that the a-helical structure of critical basic residues, required
for optimal activation of RyRs, was retained after conjugation.
4 The conjugated peptides were more effective in enhancing resting Ca2þ release, Ca2þ -induced
Ca2þ release and caffeine-induced Ca2þ release from isolated sarcoplasmic reticulum (SR) than
their unconjugated counterparts, and significantly enhanced caffeine-induced Ca2þ release from
mechanically skinned extensor digitorum longus (EDL) fibres.
5 The effect of both conjugated and unconjugated peptides on Ca2þ release from skeletal SR was
30-fold greater than their effect on either cardiac Ca2þ release or on the Ca2þ Mg2þ ATPase.
6 A small and very low affinity effect of the peptide in slowing Ca2þ uptake by the Ca2þ , Mg2þ
ATPase was exacerbated by lipoamino acid conjugation in both isolated SR and in skinned EDL
fibres.
7 The results show that lipoamino acid conjugation of A region peptides increases their membrane
permeability without impairing their structure or efficacy in activating skeletal and cardiac RyRs.
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Introduction
The ryanodine receptor (RyR) Ca2þ release channel is the
sole conduit for Ca2þ release from internal stores in the
sarcoplasmic reticulum (SR) to activate contraction in skeletal
muscle and the heart. The RyR, either alone or in combination
with the inositol 1,4,5-trisphosphate receptor (IP3R), is also
found in the endoplasmic reticulum, mitochondria, nuclear
envelope and secretory vesicles of many cell types, including
smooth muscle, neurones and lymphocytes. Despite the
importance of this ion channel, there are few drugs available
that can be used either as experimental probes for RyR activity
or for therapeutic purposes.
A 20 amino-acid peptide (peptide A), corresponding to a part
of the loop between the second and third membrane-spanning
segment of the skeletal dihydropyridine receptor (DHPR),
is a part of a naturally occurring muscle protein and is a
high-affinity activator of skeletal and cardiac RyR channels
(El-Hayek et al., 1995; Dulhunty et al., 1999; Gurrola et al.,
1999; Lamb et al., 2000; Stange et al., 2001; Dulhunty et al.,
2002). Both the DHPR and the RyR are essential for skeletal
muscle contraction (Tanabe et al., 1988). A strict alignment
(Block et al., 1988) allows physical coupling between the II–III
loop of the DHPR and the RyR to initiate skeletal-type
excitation–contraction (EC) coupling (which is independent of
external Ca2þ ). Although the A region of the II–III loop is not
required for EC coupling (Proenza et al., 2000; Wilkens et al.,
2001), it has been implicated in the overall physical interaction
between the DHPR and RyR (Ahern et al., 2001).
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A sequence of positively charged residues (El-Hayek et al.,
1995; Gurrola et al., 1999; Casarotto et al., 2000, 2001), and
the alignment of the residues along one surface of the molecule
(Casarotto et al., 2000; 2001; Green et al., 2003), are critical for
peptide A to activate RyR channels. Modified A peptides
having the most stable a-helical structure are the strongest
activators of the RyR and have a surface orientation of
positively charged residues similar to that in two scorpion
toxins, Imperatoxin A and Maurocalcine (Mosbah et al., 2000;
Green et al., 2003). The toxins, like the peptide, are high-
affinity activators of the RyR and thought to bind to a similar
site on the RyR (Tripathy et al., 1998; Gurrola et al., 1999;
Green et al., 2003). The A peptides are potentially useful as
probes for RyR channel activity and would be more useful if
they could be modified for membrane permeability without
loss of function.
In this study, we have made the A peptides membrane
permeable by conjugating them to C12 or C10 lipoamino acids,
to alter their physico-chemical properties. Lipoamino acids are
a amino acids with long alkyl side-chains, which can enhance
the membrane permeability, intestinal absorption and meta-
bolic stability of peptides and have been investigated
extensively in drug delivery (Toth et al., 1999; Toth & Keri,
2003). We have assessed the permeability of the lipoamino
acid-conjugated A peptides, examined their structure and
assessed their ability to release Ca2þ from cardiac and skeletal
SR vesicles and from the SR in skinned skeletal muscle fibres.
The results show that the lipid modification of the A peptides
(a) increased their permeability, (b) did not significantly alter
their structure, (c) enhanced their ability to activate Ca2þ
release from isolated SR, (d) did not significantly alter their
ability to activate the RyR in skinned muscle fibres and
(e) enhanced a lower-affinity action of the peptide on Ca2þ
uptake by the Ca2þ , Mg2þ ATPase in the SR.
Methods
Peptides and peptide synthesis
The A-series peptides, A1, A2, A1(D-R18) and A2(D-R18)
(Table 1) were synthesised by the JCSMR Biomolecular
Resource Facility using an Applied Biosystems 430A Peptide
Synthesiser with purification to 98–100% using HPLC and
mass spectroscopy. Stock peptide solutions (B2mM) were
prepared in H2O and frozen in 20 ml aliquots (Dulhunty et al.,
1999).
Lipid conjugation
Lipoamino acids, a-aminodecanoic acid and a-aminododeca-
noic acid were synthesised (Gibbons et al., 1990), purified,
triturated with acetonitrile, then re-crystallised. The a-amino-
decanoic acid was coupled to the resin once (or twice), then
coupled to peptide A2 (D-R18) to yield A2(D-R18)-C10 (or
A2(D-R18)-2C10). Likewise, a-aminododecanoic acid was
coupled once to A2(D-R18) to obtain A2(D-R18)-C12.
Sequences of A2 and A2(D-R18) and the lipoamino acid
structures are:
A2 = TSAQKAKAEERKRRKMARGL
A2(D-R18) = TSAQKAKAEERKRRKMA(D-R)GL
A2(D-R18)-C10
A2(D-R18)-2C10
A2(D-R18)-C12
where    -C10 -2C10 -C12
Membrane permeability assessment
Caco-2 (human colon carcinoma; American Type Culture
Collection) epithelial cell lines were cultivated as monolayers
on permeable filters (Artursson & Karlsson, 1991). The cells
were maintained in tissue culture flasks (Nunc, Roskilde,
Denmark) and seeded at B5 105 cells cm2 into 6.5mm
Transwellss with polycarbonate membranes (0.4 mm pore,
Costar, Cambridge, U.S.A.). The culture medium (Dulbecco’s
modified Eagle’s medium, Gibco Paisley, Scotland) was
supplemented with 10% foetal calf serum, 1% nonessential
amino acids, 1% L-glutamine and 1% penicillin and strepto-
mycin. The media was replaced every 48 h, with 0.1ml on the
apical side and 0.6ml on the basolateral side. Cells with a
passage number of 55 were used in experiments. The integrity
of the monolayers was monitored by the transepithelial
electrical resistance (TEER) and mannitol permeability.
Apparent permeability
At 30 days after seeding, the cells were washed and
equilibrated in Hanks’ balanced salt solution (HBSS) at 371C
on apical and basolateral sides. The cells were placed in new
wells containing 0.6ml of HBSS. In all, 200mM of test
compound was added to the apical side and the inserts
transferred to new wells every 30min over 3 h. Concentrations
of test compounds in the basolateral solution were determined
by liquid chromatography–mass spectrometry (LC–MS). The
apparent permeability coefficient Papp (cm s
1) was calculated
as:
Papp ¼ ðDQ=DtÞ=AC0
where DQ/Dt is the permeability rate, A is the surface area of
the monolayer and C0 is the initial concentration of the peptide
on the apical side. The mannitol permeability assay was
performed using D-Mannitol-1-14C, (Sigma) as described
previously (Artursson et al., 2001).
Electrical measurements
TEER was measured at 371C with a Millicell-electrical
resistance system (ERS). The Caco-2 monolayers were
incubated for 30min, and the electrodes equilibrated for
15min, in HBBS before TEER measurements 1 day and
30min before, and immediately after, the experiment. The
filter resistance without the cells (4–5O cm2) was subtracted
from TEER values.
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LC/MS analysis
A Perkin-Elmer Sciex API 3000 combined with Shimadzu
HPLC was used to detect and measure peptides. A volume of
10 ml of HBBS/peptide sample was injected into the LC/MS.
An Agilent C18 column (Zorbax 5mm SB-C18 2.1 50mm2)
with C18 guard column and 1 : 10 splitter was used. Mobile
phase A was 0.1% formic acid in H2O; B was 90% acetonitrile
with 0.1% formic acid. The solvent gradient was started with
0% B for 0.6min, increased to 100% B at 1.6min, retained for
1.9min and decreased to 0% B in 0.1min at a constant flow of
0.2mlmin1. Standards were prepared from 0.001 to 5mM.
Standard curves achieved R240.999.
Nuclear magnetic resonance (NMR) spectroscopy
Peptides A2(D-R18), A2(D-R18)-2C10 and A2(D-R18)-C12
were dissolved in 10% D2O/90% H2O to a final concentration
of B2mM at pH B5.5. NMR spectroscopy and subsequent
analysis were then performed as described previously (Casar-
otto et al., 2000; 2001).
Isolation of SR vesicles
Skeletal SR was isolated from the back and leg muscles of New
Zealand White rabbits, and heavy SR was collected from the
35–45% (wv1) interface of a discontinuous sucrose gradient,
centrifuged and resuspended (Ahern et al., 1994). Cardiac SR
was prepared from sheep heart (Chamberlain & Fleischer,
1988; Laver et al., 1995). Vesicles were frozen and stored either
in liquid N2 or at 701C.
Ca2þ release
Extravesicular Ca2þ was monitored at 710 nm with the Ca2þ
indicator, antipyrylazo III, using a Cary 3 spectrophotometer
(Dulhunty et al., 1999). Identical release experiments were
performed at 790 nm, to detect Ca2þ -independent changes
in optical density (OD), which would alter the Ca2þ release
measurement. The cuvette solution was stirred continuously
and temperature controlled at 251C. A typical Ca2þ -release
experiment is shown in Figure 3. Skeletal SR (100 mg of
protein) was added to the cuvette solution (final volume of
2ml), containing (mM): KH2PO4, 100 (pH¼ 7); MgCl2, 4;
Na2ATP, 1; antipyrylazo III, 0.5). Ca
2þ , Mg2þ -ATPase
activity was suppressed with thapsigargin (200 nM; Sagara &
Inesi, 1991). The same solutions were used with cardiac SR,
except that an ATP-regenerating system – phospho(enol)pyr-
uvate (5mM) and pyruvate kinase (25 mgml1) – was added.
OD calibration curves were obtained daily. The same
conditions were used for Ca2þ accumulation experiments,
except that the concentration of antipyrylazo III was 0.2mM.
Control experiments, performed either without SR vesicles
or when the SR vesicles were blocked with thapsigargin,
ruthenium red and ionophore, showed that addition of the
-2C10 conjugated peptides elicited a step change in OD and
then a slow increase. This artefactual change in OD was
similar for all -2C10 conjugated peptides, and increased with
peptide concentration from negligible levels at p1mM peptide
to values equivalent to Ca2þ release rates of B573 and
64710 nmolmg1min1 at 5 and 30mM peptide, respectively.
Measurements of Ca2þ -release rate obtained in experiments
where -2C10 conjugated peptide was added to Ca2þ -loaded
vesicles were corrected for this artefact by subtracting the
appropriate value. It was possible that this intrinsic optical
effect was due to an isomer A2(D-R18)-2C10. The peptide
A2(D-R18) is made with optically pure L-amino acids and
D-R18. The lipoamino acid (C10) was a racemate (L-C10 and
D-C10), so that one C10 conjugation gave two diastereomers
and the second coupling gave four diastereomers. These
diastereomers were separated by HPLC and two major
fractions obtained. Fraction 1 produced much less artefactual
change in OD but retained its efficacy in activating Ca2þ
release, while fraction 4 had less functional activity and
produced a strong artefactual response.
Skinned fibre techniques
Experiments were performed at 23721C and chemicals
obtained from Sigma, except where noted. Mechanically
skinned segments of single extensor digitorum longus (EDL)
muscle fibres from the rat were connected to a force transducer
(AME801, SensoNor, Horten, Norway), and bathed in a
standard high [Kþ ] solution mimicking the normal environ-
ment (Lamb & Stephenson, 1994) and containing (mM): Kþ ,
126; Naþ , 37; 1,6-diaminohexane-N,N,N0,N0-tetraacetic acid
(HDTA) (Fluka, Buchs, Switzerland), 50; total ATP, 8.0; total
creatine phosphate, 10.0; total magnesium, 8.5; HEPES, 90;
NaN3, 1.0; total EGTA, 0.05, with pCa (i.e. log10[Ca2þ ]) 7.1
and pH 7.1070.01 (free [Mg2þ ], 1mM; osmolality,
29575mosmol kg1). The SR was fully emptied of Ca2þ by
pre-equilibrating the fibre in standard solution with 0.5mM
EGTA (pCa48) for 10 s and then exposing it to the Full
Release Solution (similar solution with 30mM caffeine,
0.05mM free Mg2þ and 0.5mM EGTA, pCa48). The time
integral (area) of the force response upon emptying the SR
with the Full Release Solution indicated the amount of Ca2þ
present in the SR (Lamb et al., 2001).
To test the sensitivity to 8mM caffeine (e.g. Figure 9), the
SR was loaded with Ca2þ to a set level (close to that in
the fibre endogenously) by exposing the fibre for a set period
(usually 15 s) to a solution buffered at pCa 6.7 with 1.0mM
total EGTA (Lamb et al., 2001). The fibre was then
equilibrated in standard weakly Ca2þ -buffered solution
(1mM Mg2þ , 0.05mM EGTA, pCa 7.1) for 20 s, with or
without peptide, and exposed to a similar solution with 8mM
caffeine for 15 s, before fully depleting the SR of its remaining
Ca2þ with the Full Release Solution. Maximum Ca2þ -
activated force in each fibre was determined using a 50mM
Ca-EGTA (pCa 4.7) (‘Max’) solution.
To examine the effect of a peptide on Ca2þ accumulation
(Figure 10), the fibre was subjected to repeated load-deplete
cycles in which the SR was loaded for a set period with peptide
present or absent, and then emptied of all Ca2þ with the
standard Full Release Solution (without peptide) to ascertain
the total Ca2þ accumulated. When loading in standard 1mM
Mg2þ , the load solution was at pCa 6.7 (1mM total EGTA),
but when loading at 10mM Mg2þ the free [Ca2þ ] was
increased to pCa 6.4. Before loading, the fibre was pre-
equilibrated for 1min in a solution with 0.5mM EGTA
(pCa48) with or without peptide. To examine the Ca2þ
sensitivity of the contractile apparatus, a fibre was exposed to
matched sequences of solutions, both with and without the
peptide, in which the [Ca2þ ] was heavily Ca2þ -buffered
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(50mM total EGTA replacing HDTA) at progressively higher
levels (pCa 6.7–4.7) (Lamb & Stephenson, 1994). The steady-
state force produced at each pCa was expressed relative to the
respective maximum, and the force–pCa relationship was best
fit with a Hill curve to give the pCa producing half-maximal
force (pCa50) and the Hill coefficient.
Statistics
Average data are given as mean7s.e.m. for nX4, or
mean7s.d. for n¼ 3. The significance of the difference
between control and test values was tested using a Student’s
t-test.
Results
Membrane permeability of the peptides
The peptide sequences are shown in Table 1. The novel
A2(D-R18) contained two modifications of the native A1
sequence, which increase structural stability. Ser17 was
mutated to an alanine (Casarotto et al., 2000) and the
L isomer of Arg18 was replaced by the D isomer (Green
et al., 2003). The apparent permeabilities of A2(D-R18) and
A2(D-R18)-2C10 were measured and compared with a single
tail of the same chain length, A2(D-R18)-C10. The amount
of peptide transported across the Caco-2 cell monolayer
increased with lipoamino acid conjugation (Figure 1a).
The apparent permeabilities were 4.1770.5E–08 cm s1 for
A2(D-R18), 24.771.46E–08 cm s1 for A2(D-R18)-2C10 and
91.576.1E–08 cm s1 for the single -C10 conjugate.
The relatively small permeability for A2(D-R18)-2C10 was
surprising, but is likely to reflect lower than expected
concentrations in the donor compartment because the more
hydrophobic peptide was adsorbed onto the surface of the
sample well (Artursson & Karlsson, 1991). In contrast, since
A2(D-R18)-C10 would have no significant plastic adsorption,
its apparent permeability is a more accurate reflection of the
true permeability of the tailed peptides. TEER values
(Figure 1b) and the mannitol permeability assay indicated
that the cells remained in good condition. TEER remained
X30% of control in all cases. Toxicity is indicated by a fall to
o10% of control (Ingels et al., 2002). A smaller fall in TEER
over the experimental period with both the permeable and
impermeable compounds was not indicative of toxicity.
Mannitol permeability, measured in parallel with compound
permeability, remained between 2.4E–07 and 2.9E–07 cm s1
and well within the normal range of 1.8E–07 to 1.17E–06
(Artursson et al., 1996). Mannitol is restricted to the
paracellular pathway across the tight junctions and its
permeability indicates the tightness of the junction. The
permeability will significantly increase if cells are damaged,
as mannitol diffuses between the donor and the receiver
compartments.
Since lipophylic compounds are excluded from paracellular
pathways, it is well recognised that their permeability reflects
their movement across the cell membranes, provided the cells
are not damaged (Wong et al., 2002). Since TEER and
mannitol permeability indicated that the cells in this study
remained in good condition, the increase in permeability
Table 1 Effects of various A-series peptides on the
initial rate of CICR from cardiac SR vesicles
Relative release rate
Peptide 10 mM 30mM
A1 Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys ArgArg
Lys Met Ser Arg Gly Leu
2.1570.23* 1.8370.15*
(4) (9)
A2 Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg
Lys Met Ala Arg Gly Leu
2.0370.03* 2.6170.34*
(5) (5)
A2(D-R18) Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys
Arg Arg Lys Met Ala Arg Gly Leu
3.0270.50* 2.7770.39*
(6) (9)
A2(D-R18)-C12 1.5870.15 0.7770.17
(3) (3)
A2(D-R18)-2C10 2.4570.23* 4.5171.12*
(3) (4)
The rate of CICR in the presence of 10 or 30mM peptide is
expressed relative to that with no added peptide (control).
Number of experiments is given in brackets. The sequence for
each of the peptides is given. Residues altered from the native
A1 sequence are highlighted. The Ser to Ala mutation in A2,
A2(D-R18) is shown in bold type, and L-Arg to D-Arg
replacement in A2(D-R18) is shown in bold italics. -C12
indicates that the peptide conjugated to a single -C12 tail,
while -2C10 indicates conjugation to two -C10 tails. Asterisks
indicate that the data are significantly different from control
(i.e. 1.0).
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Figure 1 Conjugation of two -C10 lipid tails to A2(D-R18) allows
the peptide to cross Caco-2 cell membranes. (a) The apparent
permeability of Caco-2 cell monolayers for peptides A2(D-R18),
A2(D-R18)-C10 and A2(D-R18)-2C10. Each bar show the
mean7s.d. for Papp obtained from three experiments. The asterisks
indicate a significant difference from data obtained with A2(D-R18).
(b) Average TEER measurements obtained from the monolayer
before and after permeability measurements using A2(D-R18)
(n¼ 3), A2(D-R18)-C10 (n¼ 4) and A2(D-R18)-2C10 (n¼ 4).
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of the -C10 conjugates is indicative of increased membrane
permeability.
Structure of A2(D-R18) lipid-conjugated peptides
The complete NMR assignments were determined using
standard two-dimensional methods with TOSCY experiments
(Bax & Davis, 1985) to identify spin types and NOESY
experiments (Kumar et al., 1980) for specific sequence assign-
ments. The extent of a-helical structure was assessed from
NOE cross-peaks, which indicate that two proton atoms are
separated byBo5 A˚. Adjacent amide backbone protons in an
a-helix are separated by Bo2.8 A˚ and typical NOE patterns
reflecting a-helical structure are shown in Figure 2.
The spectrum for A2(D-R18) (Figure 2a) indicates a helix
extending throughout the entire peptide from residue 1 to 20,
with a helical structure comparable to that in A1(D-R18)
(Green et al., 2003). Fewer NOESY cross-peaks were present
in the spectrum for the active fraction 1 of A2(D-R18)-2C10
(Figure 2b). These cross-peaks, as well as the a-proton
chemical shift, indicate a helical structure between residues 2
and 15 (Casarotto et al., 2001). Thus, the structures of the two
residues closest to the lipophilic tail attachment were altered,
but the key basic residues required for RyR activation (11–15)
remained helical. Differences in the chemical shift patterns for
A2(D-R18) and A2(D-R18)-2C10 are due to environmental
changes caused by the attachment of the lipoamino acid tail to
the N-terminus.
The spectrum for the less active fraction 4 of A2(D-R18)-
2C10 (not shown) had the same number of NOE cross-peaks
as fraction 1, but interestingly residues 11–15 were not fully
contained within the helix. The loss of helical structure of
residues 11–15 is (a) consistent with the low activity of fraction
4 (see Methods and Results) and (b) showed that isomerisation
at the junction between the peptide and the lipid could cause
small changes in peptide structure away from the conjugation
point.
In contrast to the peptides A2(D-R18) and Fraction 1 of
A2(D-R18)-2C10, A2(D-R18)-C12 displayed an NOE cross-
peak pattern indicative of a partial helical structure in the
critical 11–15 amino-acid region (not shown). This may
explain the reduced function of this peptide (Table 1), and is
consistent with our hypothesis that this stretch of basic
residues must be structurally ordered in a helical manner for
optimal activation.
Lipoamino acid conjugation enhances the ability
of peptides to release Ca2þ from SR
Ca2þ release from skeletal SR It was shown previously
that mutating Ser 17 in the A1 peptide to an alanine (A2
peptide) increased its efficacy at inducing Ca2þ release from
thapsigargin-blocked, skeletal SR (Casarotto et al., 2000).
Furthermore, replacing the L isomer of Arg18 in A1 by the D
isomer, to give A1(D-R18), also increased the efficacy (Green
et al., 2003) (e.g. see Figure 3). We show here that a peptide
with both changes, A2(D-R18), is even more effective than the
peptides with either change alone (Figure 4). Importantly,
when A2(D-R18) was double conjugated with -C10, to form
A2(D-R18)-2C10, it became considerably more effective still,
with the AC50 for resting Ca
2þ release decreasing B5-fold to
B3 mM and the maximum release rate more than doubling
(Figure 4a). Furthermore, whereas A2(D-R18) did not evoke
net release of Ca2þ in the absence of thapsigargin (Figure 3f),
A2(D-R18)-2C10 did so (Figure 3g).
Fractionation of A2(D-R18)-2C10 yielded (a) an active
isomer (fraction 1), which induced Ca2þ release with little
intrinsic absorbance change (see Methods) and (b) a less active
fraction 4, which had strong intrinsic effects. Resting Ca2þ
release was similar for the racemic mixture and the active
isomer at p20mM (Figure 4a). The peptides also enhanced
CICR and caffeine-induced Ca2þ release from the skeletal SR
(Figure 4b). A2(D-R18)-2C10 was more active than A2(D-R18)
and there was a further increase in activity with fraction 1.
Ca2þ release from cardiac SR Both conjugated and
unconjugated peptides were active on cardiac SR, but their
effects were small and in marked contrast to the large effect on
skeletal SR. The unconjugated A2(D-R18) at 30 mM had little,
if any, effect on the rate of release from the thapsigargin-
treated cardiac vesicles (Figure 5a). Interestingly, double -C10
conjugation of the peptide greatly increased its ability to
induce resting Ca2þ release, with fraction 1 of A2(D-R18)-
2C10 apparently being more effective than the racemic mix-
ture (Figure 5a). In contrast, similar lipoprotein conjuga-
tion of luteinising hormone-releasing hormone (LHRH),
another small peptide with an unrelated sequence
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Figure 2 Conjugation of two -C10 lipid tails to A2(D-R18) does
not significantly alter the helical structure of the peptide in the
region of critical residues 11–15. Amide–amide regions of the
NOESY spectra of peptides A2(D-R18) (a), and the active isomer of
A2(D-R18)-2C10 in HPLC fraction 1 (F1) (b). Connected iþ i1
NOEs are shown for residues 11–15 in (a, b). These residues are the
RKRRK sequence, whose helical structure is required for optimal
RyR activation. The spectra for both peptides indicate that they
contain a substantial helical structure that includes residues 11–15.
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GHWSYTGLRPG-NH2, caused no increase in resting Ca2þ
release (Figure 5a). The A1 and A2 peptides had a mild
potentiating effect on CICR from cardiac SR vesicles and the
effect of A2(D-R18) was similar (Table 1). In accord with the
findings on resting Ca2þ release, double -C10 conjugation of
A2(D-R18) enhanced its potentiating effect on CICR, with
fraction 1 being even more efficacious with an AC50 of B1mM
(Figure 5b). Interestingly, single C12 conjugation of A2(D-R18)
evidently interfered with the ability of the peptide to enhance
CICR (Table 1).
In control experiments, Ca2þ release induced by the
peptides was shown to depend on RyR channels and
thapsigargin shown to block the Ca2þ ATPase (Figure 6).
Ruthenium red blocked CICR (Figure 6a and b) and Ca2þ
release induced with 1 mM A2(D-R18)-2C10 (Figure 6c and d).
[Ca2þ ] did not fall after adding ruthenium red because Ca2þ
pump activity was blocked by thapsigargin. A small residual
release in ruthenium red was blocked by 10mM Mg2þ
(Figure 6f; 10mM Mg2þ is a strong RyR antagonist – see
skinned fibre results below). Similarly, Ca2þ release induced
by 5mM A2(D-R18)-2C10 was fully blocked by ruthenium red
(Figure 6e), with the OD measurement showing only the small
artefactual change caused by the conjugated peptides (see
Methods).
Lipoamino acid-conjugated peptides slow the rate of SR
Ca2þ uptake Lipoamino acid conjugation exacerbated an
effect of the peptides on the Ca2þ pump. In skeletal SR, Ca2þ
accumulation was measured after adding 50 mM Ca2þ to the
cuvette (Figure 7a). The decline in [Ca2þ ] (slope A, Figure 7a)
reflected the net Ca2þ flux (uptake by the pump minus the
efflux through the RyR). A2(D-R18)-2C10 was more effective
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Figure 3 Conjugation of two -C10 lipid tails to A2(D-R18)
enhances its ability to release Ca2þ from skeletal SR vesicles. (a)
A full Ca2þ release experiment with addition of SR vesicles (first
arrow), four additions of 7.5mM Ca2þ with subsequent Ca2þ uptake
into the SR (four short arrows). Thapsigargin addition to block the
Ca2þ , Mg2þ ATPase (sixth arrow), followed by 20 mM A2(D-R18)
(seventh arrow), ruthenium red (RR, eighth arrow) and the Ca2þ
ionophore (A22187, ninth arrow). Release with 20 mM A1 is shown
in (b), 20 mM A1(D-R18) in (c) and 1.5 and 5.0mM A2(D-R18)-2C10
in (d, e), respectively. The line at the start of the Ca2þ release
indicates the initial rate of release. Effects of the peptides in the
absence of thapsigargin are shown in (f) (20mM A2(D-R18)) and (g)
(5 mM A2(D-R18)-2C10).
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Figure 4 A2(D-R18)-2C10 enhances resting Ca2þ release, caffeine-
induced Ca2þ release and Ca2þ -induced Ca2þ release from isolated
skeletal SR. Average data are shown for rates of resting Ca2þ release
(a) and caffeine-induced Ca2þ release or Ca2þ -induced Ca2þ release
in (b). Rates of release are given in nmolmg1min1. In (a), the
vertical axis is split to display the rates of release with peptides
A2 (n¼ 10), A1(D-R18) (n¼ 4–6) and A2(D-R18) (n¼ 4–6), as well
as the greater rates of release with the racemic (unfractionated)
A2(D-R18)-2C10 (n¼ 7–8) and the active isomer in fraction 1 (F1)
of A2(D-R18)-2C10 (n¼ 4–6). In (b), average data for 0.76mM
caffeine-induced Ca2þ release (left) or 10 mM Ca2þ -induced Ca2þ
release (right) under control conditions (control, n¼ 4) and with
5 mM A2(D-R18) (n¼ 4), the racemic A2(D-R18)-2C10 (n¼ 4) and
fraction 1 (F1) of A2(D-R18)-2C10 (n¼ 4). Note that the low
[caffeine] was used to obtain a slope that was low enough to see a
clear effect of the peptide.
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than the unconjugated A2(D-R18) in reducing Ca2þ accumu-
lation (Figure 7b) – consistent with their relative effects on
Ca2þ efflux. After adding ruthenium red, accumulation (slopes
B and C, Figure 7) reflected Ca2þ uptake alone and was
reduced minimally by 25mM A2(D-R18) (second column), and
reduced further by 5–10 mM A2(D-R18)-2C10. Notably, the
decrease in Ca2þ uptake rate with 5mM of the -2C10 conjugated
peptide to 0.8–0.5 of control is in contrast to the 10,000-fold
increase in resting Ca2þ release rate with the same peptide
concentration (see Figure 4 above).
The protocol was altered with cardiac SR because the SR
failed to accumulate 50mM Ca2þ , but coped with a smaller
pulse of 7.5mM Ca2þ (Figure 8a and b). The effect of
ruthenium red was small (Figure 8), indicating that the leak
through the RyR was only small, most likely due to (a) there
being excess longitudinal SR (which lacks RyRs), since the
cardiac preparation was not fractionated by sucrose gradient
(see Methods) and (b) low loading with addition of only 7.5 mM
Ca2þ . Thus, Ca2þ accumulation was dominated by Ca2þ
uptake, even in the absence of ruthenium red. A2(D-R18) did
not alter Ca2þ accumulation, nor did unconjugated A1 nor A2
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Figure 5 A2(D-R18)-2C10 enhances resting Ca2þ release and
Ca2þ -induced Ca2þ release from isolated cardiac SR. Average rates
of resting Ca2þ release (RCR) are shown in (a) and Ca2þ -induced
Ca2þ release (CICR) in (b). In (a, b), data are shown for A2(D-R18)
(RCR – n¼ 2; CICR – n¼ 6–9), the racemic A2(D-R18)-2C10 (RCR
– n¼ 4; CICR – n¼ 3) and fraction 1 (F1) of A2(D-R18)-2C10 (RCR
– n¼ 5–7; CICR – n¼ 3–4) and for a control peptide (LHRH) with
two -C10 tails (LHRH-2C10) (n¼ 2 each for RCR and CICR). Note,
in panel b that there is some CICR even in the absence of any
peptide.
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Figure 6 Control experiments showing that Ca2þ release is
through the RyR and that the Ca2þ pump is blocked by
thapsigargin. Records show Ca2þ release from skeletal SR. Vesicles
were loaded with 4 7.5 mM Ca2þ (as in Figure 3a) and 100 nM
thapsigargin added as indicated. In (a), release in response to 10 mM
Ca2þ was blocked by 5 mM ruthenium red. In (b), 5 mM ruthenium
red added after 100 nM thapsigargin reduced the Ca2þ leak and
prevented the CICR response. In (c), release with 1mM A2(D-R18)-
2C10 was blocked by 5 mM ruthenium red. In (d, e) ruthenium red
added before 1 or 5 mM peptide, respectively, prevented release. In
(f), 10mM Mg2þ (added after ruthenium red block) caused a step
increase in optical density, but abolished residual release and the
peptide-induced response. The maintained high [Ca2þ ] after adding
ruthenium red in (a–c) indicates that the Ca2þ , Mg2þ ATPase was
blocked by thapsigargin. The heavy arrow towards the end of
records in (a–d, f) indicates the time of addition of Ca2þ ionophore
A23187 (3 mgml1) to release the Ca2þ remaining in the TC vesicles.
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(Figure 8c and d). In contrast, the racemic A2(D-R18)-2C10 at
2.5mM slowed the decline in [Ca2þ ] under all conditions to
B0.8 of control. These effects were consistent with (a) a
minimal influence of Ca2þ efflux on the measurements and (b)
inhibition of the pump by A2(D-R18)-2C10.
Effects of lipoamino acid-conjugated peptides on skinned
skeletal muscle fibres
The unconjugated A2(D-R18) potentiated caffeine-induced
Ca2þ release in skinned EDL fibres. The peptide was more
effective than A1(D-R18) (Green et al., 2003), with 0.6mM
peptide increasing both the amplitude and rate of Ca2þ release
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Figure 7 A2(D-R18)-2C10 reduces Ca2þ accumulation by skeletal
SR by increasing Ca2þ efflux through the RyR and by reducing
Ca2þ uptake by the Ca2þ , Mg2þ ATPase. (a) A record showing
skeletal SR vesicles added to the cuvette (first arrow), followed by
either H2O (control) or peptide (second arrow). Ca
2þ accumulation
measuredB30 s after adding 50 mM Ca2þ (third arrow) (line A), and
then after addition of ruthenium red (fourth arrow) to block the
RyR (line B). When extravesicular Ca2þ was reduced to resting
levels, a second bolus 50 mM Ca2þ was added (fifth arrow) and Ca2þ
uptake measured (line C). The rate of accumulation after addition of
ruthenium red (slopes B and C) reflected Ca2þ uptake by the Ca2þ ,
Mg2þ ATPase. Average data corresponding to slopes A, B and C
are given in (b–d), respectively. The first bin in each graph shows
control data (with the volume of H2O normally added with 25 mM
peptide). The second bin shows data with 25 mM A2(D-R18), while
the third, fourth and fifth bins show data with 1, 5 and 10 mM
A2(D-R18)-2C10, respectively. Each bin gives mean7s.d. for three
observations. Asterisks indicate a significant difference from
control.
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Figure 8 A2(D-R18)-2C10 inhibits Ca2þ uptake by the cardiac
Ca2þ ,Mg2þ ATPase. (a, b) Records of a pair of experiments with
cardiac SR vesicles. Either water (control) or peptide was added (not
shown). Ca2þ accumulation was measured after each of two
additions of 7.5 mM Ca2þ (lines 1 and 2, respectively) – (a) in the
absence of ruthenium red (RR); (b) ruthenium red added before
Ca2þ (þRR). (c, d) Average data under control conditions (with
the volume of H2O added with 30 mM peptide) and in the presence of
the peptides. Four bins are shown under each condition: slope
1RR (1RR), slope 2RR (2RR), slope 1þRR (1þRR) and
slope 2þRR (2þRR). The legend in (c) also applies to (d). The
influence of RyR activity on uptake, that is, uptake in the presence
and absence of RyR activity can be assessed by comparing the black
(1RR) with the grey filled bins (1þRR) or the narrow (2RR)
with the wide stippled bins (2þRR). (c) A2(D-R18) at 10 and
30 mM (n¼ 5), and Fraction 1 of A2(D-R18)-2C10 at 2.5 and 10 mM
(n¼ 5–7). (d) A1 and A2 at 10 and 30 mM (n¼ 5 for each).
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(Table 2). This effect of the peptide was substantially reversed
within 2min after washout of the peptide (not shown).
A2(D-R18)-2C10 also potentiated caffeine-induced re-
sponses (Figure 9), with a significant increase in amplitude at
0.6 mM and a significant effect on rate at 10mM (Table 2). In
contrast to Ca2þ release from isolated SR (Figures 3 and 4),
conjugation seemingly reduced the relative effectiveness of the
peptide in skinned fibres. However, this was almost certainly
because the strong partitioning of the hydrophobic peptide
into the membranes meant that the 20 s period allowed for full
equilibration with the RyR was insufficient. (The 20 s
equilibration period could not be increased because the peptide
was likely to cause too great a loss of Ca2þ from the SR before
the exposure to 8mM caffeine.) Strong partitioning into the
membrane was further indicated by the fact that the effect of
A2(D-R18)-2C10 on the caffeine response was only partially
reversed after410min washout. Thus, the observed effects of
A2(D-R18)-2C10 on caffeine-induced Ca
2þ release almost
certainly underestimate its efficacy.
The enhancement of caffeine responses by A2(D-R18)-2C10
was evidently due to an effect on Ca2þ release from the SR,
not on the Ca2þ sensitivity of the contractile apparatus.
Firstly, the force response when emptying the SR of its
remaining Ca2þ after exposure to 8mM caffeine was smaller
when peptide had been present in the 8mM caffeine solution
(Figure 9). Such a reduced response indicates that the presence
of the peptide in the 8mM caffeine solution caused greater
depletion of Ca2þ in the SR. Secondly, direct examination of
the contractile apparatus showed that A2(D-R18)-2C10 (at
3mM) had no effect on maximum force or Ca2þ sensitivity
(pCa50 and Hill coefficient: 5.9670.01 and 4.470.6, and
5.9670.01 and 4.270.7, with and without peptide, respec-
tively; P40.05, Student’s paired t-test, n¼ 4).
A2(D-R18)-2C10 substantially inhibited net Ca
2þ accumu-
lation by the SR (Figure 10a). In these experiments, where the
SR was initially empty of Ca2þ , it was possible to equilibrate
the fibres with peptide for 1min before testing its effect on
Ca2þ accumulation. The effect of the conjugated peptide on
Ca2þ accumulation became greater with repetition (stabilising
after B3 repetitions), consistent with a slow time-course for
full equilibration of the peptide within the fibre. A2(D-R18)-
2C10 (10mM) reduced the net uptake rate to 1874% of control
Table 2 Effect of peptides on the force response to 8mM caffeine in rat skinned EDL fibres
Peak response to 8mM caffeine (% of
maximum Ca2+-activated force)
Rate of force rise to 8mM caffeine (% Ca2+-
activated maximum force per sec)
Control Test 1 Test 2 Control Test 1 Test 2
A2(D-R18) (0.6 mM) (n¼ 7) 1975.6 5175.6* 58710.2* 671.8 2576.5* 3277.0*
A2(D-R18) (3 mM) (n¼ 4) 3179.6 79710* 7775.4* 973.6 74720* 70715*
A2(D-R18)-2C10 (0.6mM) (n¼ 5) 22712 37712* 5279.1* 1278.0 1676.2 2176.6
A2(D-R18)-2C10 (3mM) (n¼ 3) 3579.3 59721 44720 1273.2 29713.7 23710.2
A2(D-R18)-2C10 (10mM) (n¼ 3) 15715 74712.3* 8477.5* 271.6 2377.5* 3478.5*
In each skinned fibre, the force response to 8mM caffeine was measured twice in the absence of peptide (and averaged) and then twice in
the presence of the peptide (tests 1 and 2) (see Figure 9), and expressed as a percentage of the maximum Ca2+-activated force in that fibre.
The table shows the mean7s.e.m. data obtained in the indicated number of fibres (n). Note that, although the size of control response to
8mM caffeine could differ somewhat between fibres, it was highly reproducible within a given fibre (e.g. Figure 9), and that paired control
and test data were always obtained in each fibre.
*Significant difference (Po0.05) between control and test response (Student’s one-tailed paired t-test).
Figure 9 A2(D-R18)-2C10 potentiates caffeine-induced Ca2þ release in a skinned EDL fibre. A skinned EDL fibre was subjected
to repeated cycles in which the SR was emptied of all Ca2þ and then reloaded to a set level and the responsiveness to 8mM caffeine
tested. The response to 8mM caffeine was greatly potentiated by 10 mM A2(D-R18)-2C10. After testing the response to 8mM
caffeine, the SR was depleted of its remaining Ca2þ by exposure to the Full Release Solution, with the area of the resulting force
response being indicative of the amount of Ca2þ that was in the SR. When 8mM caffeine elicited a bigger force response, and hence
more Ca2þ release, the amount of Ca2þ left in the SR decreased. Note that the ‘area’ of the force response to 8mM caffeine cannot
be directly compared to that when fully releasing the Ca2þ because of the very different levels of Ca2þ buffering in the two cases.
The peptide was added 20 s before testing the responsiveness to 8mM caffeine. ‘Max’ indicates maximum Ca2þ -activated force for
the fibre.
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(on the third repetition in peptide) (n¼ 6 fibres). The effect was
slowly reversed by washout (taking B10min for near full
recovery, legend to Figure 10). The effect of the peptide in
reducing net Ca2þ accumulation was consistent with it
enhancing Ca2þ efflux through the RyR during the Ca2þ -
loading period. The greater effect with successive repetitions
and slow washout are consistent with retarded equilibration of
the peptide at its active site.
The possibility that the conjugated peptide also slowed Ca2þ
uptake by the Ca2þ pump was examined by blocking Ca2þ
efflux with 10mM free Mg2þ – a potent inhibitor of the RyR
(Lamb & Stephenson, 1994). Under such circumstances, 10mM
of A2(D-R18)-2C10 reduced net uptake to only 7178% of
control (n¼ 6 fibres, Po0.05) (e.g. Figure 10b). The fact
that uptake still declined when the RyR was disabled indicates
that the peptide directly inhibits the SR Ca2þ pump. Never-
theless, it is apparent that most of the reduction in net Ca2þ
accumulation observed at normal [Mg2þ ] (e.g. Figure 10a) was
due to the peptide potentiating the Ca2þ efflux from the SR
during Ca2þ loading. These results are in close accord with
those found in the skeletal SR vesicles.
Discussion
We find that peptides, with sequences based on the A region of
the skeletal muscle DHPR II–III loop, become permeable in a
Caco-2 cell line assay following lipoamino acid conjugation.
Importantly, the conjugation did not significantly alter the a-
helical structure of residues that are critical for high-affinity
activation of RyR Ca2þ channels, and did not interfere with
the ability of the peptides to release Ca2þ from the SR. In fact,
the conjugation increased the efficacy of the peptides in
inducing Ca2þ release from both skeletal and cardiac SR.
Permeability of lipoamino acid-conjugated peptides
As shown previously with other peptides (Wong et al., 2002),
the lipoamino acid conjugation enhanced the ability of
the poorly absorbed native peptides to cross the epithelial
cell layer. In order for a compound to be well absorbed, it
should have an apparent permeability in Caco-2 monolayers
of B1 106 cm s1 (Artursson & Karlsson, 1991). Since
A2(D-R18)-C10 had a Papp value of 0.97 106, it should be
well absorbed in vivo. Passive transport pathways across the
epithelium are through tight junctions and across the apical
and basolateral cell membranes (Artursson et al., 2001; Wong
et al., 2002). The poorly permeable hydrophilic A2(D-R18)
probably diffused through tight junctions, which provide the
usual route for water-soluble compounds. The enhanced
permeability of the hydrophobic lipoamino acid conjugates
suggested that they crossed the cell membranes. The low
apparent permeability of the more hydrophobic A2(D-R18)-
2C10 (compared with A2(D-R18)-C10), can be explained by a
lower than expected [peptide] in the donor solution, due to
lower solubility and tendency to adsorb onto the chamber
wall. High adsorbance can reduce apparent permeability by at
least an order of magnitude (Artursson & Karlsson, 1991).
Structure of the conjugated peptides
The ability of the A peptides to stimulate Ca2þ release through
the RyR depends on the presence of a stretch of positively
charged amino-acid residues along one surface of the a-helical
Figure 10 Peptide A2(D-R18)-2C10 reduces net Ca2þ uptake by the SR in a skinned EDL fibre when present in the loading
solution. In (a), force responses were elicited when emptying the SR with the Full Release Solution after loading for the indicated
time, under the standard conditions with 1mM Mg2þ (pCa 6.7, 1mM total EGTA), with or without peptide. The area of the force
response is indicative of the net amount of Ca2þ loaded into the SR. The peptide reduced net Ca2þ uptake and the effect became
greater on successive repetitions (stabilising afterB3 repetitions) and was reversed only slowly by washout. The records shown are
for the third repetition after loading in the presence of the peptide, and the following control records are for the fourth load/release
cycle after washout of the peptide. In the fibre shown in (b), A2(D-R18)-2C10 caused only a small reduction in net SR Ca2þ uptake
when there was 10mM free Mg2þ in the loading solution. The reduced effect of the peptide was due to the high [Mg2þ ] inhibiting
activation of the Ca2þ release channels and preventing the peptide from increasing Ca2þ efflux from the SR during uptake. These
findings indicate that most of the reduction in net Ca2þ uptake by the peptide in (a) is due to increased Ca2þ efflux, not reduced
uptake. (Note that the rate of Ca2þ uptake is reduced in 10mMMg2þ but this effect was minimised by raising the [Ca2þ ] in the load
solution from pCa 6.7 to 6.4, so that the net Ca2þ loaded into the SR is comparable with that in (a)). In (a, b) Ca2þ release was
evoked under the standard conditions with 1mM Mg2þ .
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peptide (Casarotto et al., 2000; 2001; Green et al., 2003). The
profile of the NOESY spectra provides sufficient information
to assess the integrity of secondary structure without
performing a full structural analysis. The NOE cross-peak
pattern in the amide region showed that the helical nature of
the peptides was essentially retained despite the modification
of the N-terminus by the lipoamino acid attachment. In
particular, it was shown that the involvement of a helix for
residues 11–15 was still a requirement in order for these
peptides to release Ca2þ from the SR. This point was clearly
evident for the two fractions of A2(D-R18)-2C10 where the
stereochemistry related to the lipophilic attachment influenced
the structure of the peptide portion and hence the functional
response of the peptide. Thus, functional changes in the
conjugated peptides can be attributed to the increased
hydrophobicity of the peptide, rather than altered peptide
structure.
RyR activation by lipoamino acid-conjugated peptides
The lipoamino acid conjugation of A2(D-R18) considerably
enhanced its ability to release Ca2þ from isolated SR. Since the
control LHRH-2C10 peptide did not release Ca
2þ or enhance
CICR, the lipoamino acid tails per se did not contribute to
Ca2þ release.
Different actions of the peptides on skeletal and cardiac
SR
The effects of the A peptides on skeletal SR were significantly
stronger than the effects on cardiac SR. The lower sensitivity
of the cardiac preparation presumably reflects differences
between the binding sites or in the environment of the binding
site in different RyR isoforms. A further reflection of possible
differences in the environment of the binding site is the fact
that the active fraction 1 (F1) of A2(D-R18)-2C10 was as
effective as the racemic A2(D-R18)-2C10 in releasing Ca
2þ in
the skeletal preparation, but was substantially more effective in
the cardiac preparation (although its effect remained far less
than that on skeletal SR).
Slow equilibration of lipoamino acid-conjugated peptides
in skinned fibres
In contrast to the greater efficacy of the lipoamino acid-
conjugated peptides in releasing Ca2þ from isolated SR,
A2(D-R18)-C10 was less effective in enhancing caffeine-
induced Ca2þ release in skinned fibres when equilibration
times were brief (B20 s). However, when the preparation was
successively exposed to A2(D-R18)-C10 (with 1min equilibra-
tion during each exposure), a progressively greater effect on
Ca2þ accumulation was observed, which was attributed to
enhanced Ca2þ efflux. This indicated that equilibration of
the conjugated peptide at its active site was slower than
accumulation of the unconjugated peptide. Slow equilibration
is consistent with the hydrophobic peptide partitioning into the
lipid of the t-tubule and SR membranes that surround the RyR
and form two boundaries of the restricted space of the triad
junction (Franzini-Armstrong, 1970), as seen in the skinned
fibres with other lipid-permeable agents such as nifedipine
(Posterino & Lamb, 1998). It is also evidence that the
conjugated peptides readily permeate the cell membranes of
muscle fibres.
Lipoamino acid conjugation of the A peptides reveals
an action on the Ca2þ pump
A small and low-affinity effect of the conjugated A peptides on
the Ca2þ , Mg2þ ATPase was apparent. Since fast-twitch
skeletal and cardiac SR contain different isoforms of SR,
endoplasmic reticulum Ca2þ ATPase (SERCA), SERCA1 and
SERCA2a, respectively (MacLennan et al., 1997), the effect
is not isoform specific. A small decline in Ca2þ uptake by
skeletal SR exposed to the unconjugated A2(D-R18) suggested
that the hydrophilic peptide may have restricted access to an
inhibitory site located in a hydrophobic region of the protein.
Potential use for lipoamino acid-conjugated A peptides
Within a limited concentration range, A2(D-R18)-2C10 is a
specific activator of the skeletal RyR in SR vesicles and
skinned fibres. A2(D-R18)-2C10 at 2 mM produced an B2000-
fold increase in Ca2þ release from skeletal SR without
affecting the Ca2þ pump. At higher concentrations where
small effects on the cardiac RyR and on Ca2þ uptake by the
Ca2þ , Mg2þ ATPase were apparent, the activation of RyR1
was several orders of magnitude greater than the effects on
RyR2 or the SERCA proteins. The peptide at 20mM caused a
20,000-fold increase in Ca2þ release from skeletal SR,
compared with only a four-fold reduction in Ca2þ uptake.
The peptide enhanced caffeine-induced Ca2þ release in
skinned fibres at 0.6 mM, and at 10mM increased caffeine-
induced Ca2þ release B6-fold with only a 30% decline in
pump activity. Therefore, A2(D-R18)-2C10 is a membrane-
permeable peptide that selectively activates Ca2þ release from
skeletal SR through RyR channels at concentrations p2mM.
In conclusion, the experiments show that lipoamino acid
conjugation renders the A peptides membrane permeable,
without significantly altering either the a-helical secondary
structure of a critical region of the peptides or altering their
ability to stimulate RyR activity. The present study constitutes
proof of principal that lipoamino acid conjugation of A peptides
is a potentially promising method for developing membrane-
permeable specific stimulators of RyRs for use in vivo.
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